The Asia-Pacific region has seen a 11% increase in the number of metabolic disorders trials taking place over the past decade, the largest increase for any region worldwide.

The region now ranks in first for percentage growth in the number of trials taking place, compared to its fifth placed ranking in 2010.

These figures come from GlobalData’s extensive clinical trials database which seeks to track the number of clinical trials taking place in countries around the world, in numerous therapy areas.

Asia-Pacific

The Asia-Pacific region saw the biggest increase in metabolic disorders related trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Between 2010 and 2020, there was a 11% increase in the number of trials taking place.

In 2020, the largest proportion of trials in the region took place in China with 46.2% of all trials in the region taking place there.

India and Japan had the next largest percentage of trials taking place in the region with 13.7% and 9.9%, respectively.

Middle East

The Middle East saw a 12% decrease in the number of metabolic disorders trials taking place.

Iran saw the largest amount of trials taking place, in 2020, at 67.6%.

Trials in Israel and Saudi Arabia also made up a large proportion of the trials taking place with 22.5% and 3.6%, respectively.

Europe

Europe saw a 37% decrease in the number trials taking place.

Germany, the United Kingdom and Russia made up the most trials in the region, with 10.7%, 9.9% and 9.2%, respectively.

North America

North America saw a 38% decrease in metabolic disorders related trials taking place.

The United States saw the largest percentage of trials taking place in the region at 79%.

Canada and Mexico also made up a significant proportion of the trials taking place.

Africa

Africa saw a decrease in the number of metabolic disorders trials.

The region saw a 45% decrease in the number of trials.

Egypt made up 69% the largest proportion of trials taking place in the region.

South Africa and Algeria also made up a large amount of the trials taking place with 6.9% and 6.9%, respectively.

South and Central America

South and Central America saw the biggest decrease in metabolic disorders trials.

The number of trials in the region fell by 71% between 2010 and 2020.

Brazil saw the largest percentage of trials taking place in the region with 36.1%.